Methylphenidate

Indications

• FDA-approved for attention-deficit/hyperactivity disorder in children age 6 years and older, adolescents, and adults across immediate- and extended-release products.
• FDA-approved for narcolepsy in patients age 6 and older, usually with immediate-release tablets given two or three times daily.
• Extended-release products such as Concerta, Ritalin LA, and Jornay PM give one dose per day covering the school or work day without a midday dose.
• Used off-label to augment antidepressants in treatment-resistant depression, especially for apathy and fatigue in geriatric or medically ill adults.
• Used off-label for cancer-related fatigue, opioid-induced sedation, and apathy or cognitive slowing after traumatic brain injury or stroke.
• Off-label in preschoolers aged 4-5 years with ADHD when parent training in behavior management has failed, per AAP guidance.

Mechanism of action

• Blocks the dopamine transporter and the norepinephrine transporter, raising synaptic dopamine and norepinephrine in prefrontal cortex and striatum.
• Unlike amphetamines it does not appreciably reverse transporter flux or empty vesicular stores, so release stays activity-dependent rather than forced.
• Prefrontal norepinephrine at postsynaptic alpha-2A receptors and dopamine at D1 receptors sharpens signal-to-noise in working memory circuits.
• The d-threo enantiomer carries nearly all activity; racemic methylphenidate is about half largely inert l-threo isomer removed on first pass.
• Striatal transporter occupancy near 50 percent tracks response, and slow-rising delivery systems blunt the euphoria that drives abuse liability.

Pharmacokinetics

• Rapidly absorbed orally with immediate-release Tmax of 1-2 hours; food delays peak modestly but does not reduce total absorption of most products.
• Cleared by presystemic and hepatic de-esterification via carboxylesterase CES1A1 to inactive ritalinic acid, so clinically important CYP interactions are rare.
• Elimination half-life is 2-3 hours for immediate-release and 3.5-4 hours for OROS, yet duration of effect is set by the delivery system, not the half-life.
• Protein binding is low at 10-33 percent, volume of distribution is about 2.65 L/kg, and roughly 80 percent is excreted renally as ritalinic acid.
• The Daytrana transdermal patch bypasses first-pass metabolism and gives higher d-methylphenidate exposure than the same oral milligram dose.

Dosing

• Immediate-release: start 5 mg PO twice daily before breakfast and lunch, raise by 5-10 mg/day weekly, to a maximum of 60 mg/day divided.
• Concerta OROS: start 18 mg PO every morning and titrate weekly by 18 mg; max 54 mg/day in children 6-12 and 72 mg/day in teens and adults.
• Ritalin LA and Aptensio XR start at 10-20 mg each morning; Jornay PM is taken in the evening starting at 20 mg for next-morning onset, max 100 mg/day.
• Daytrana patch starts at 10 mg/9 h applied 2 hours before effect is needed and removed after 9 hours; titrate weekly through 15, 20, and 30 mg patches.
• No renal or hepatic adjustment is labeled; hold or reduce dose for weight loss, insomnia, or rising blood pressure rather than pushing the dose higher.
• No pharmacologic taper is needed, but stopping chronic high doses abruptly can unmask fatigue, hyperphagia, and depressed mood for several days.

Adverse effects

• Decreased appetite in 25-35 percent, insomnia in 12-20 percent, headache, abdominal pain, irritability, and dry mouth are the usual dose-related effects.
• Mean rises of about 2-4 mmHg in blood pressure and 3-6 bpm in heart rate; a minority develop clinically meaningful hypertension or tachycardia.
• Growth velocity slows by roughly 1-2 cm and 1-3 kg over the first 1-3 years of continuous treatment in children, with partial catch-up afterward.
• New psychosis or mania occurs in about 0.1 percent; hallucinations at usual doses call for stopping the stimulant rather than adding an antipsychotic.
• Priapism, peripheral vasculopathy including Raynaud phenomenon, and emergent motor or vocal tics are labeled warnings that usually prompt a change.
• Sudden cardiac death has been reported in patients with structural cardiac disease, so screen personal and family cardiac history before starting.

Monitoring

• Baseline height, weight, blood pressure, pulse, cardiac and family sudden-death history, plus screening for tics, psychosis, and substance misuse.
• Recheck pulse, blood pressure, and weight at each visit and plot height and weight on growth charts at least every 6 months in children.
• Track response with a validated scale such as ADHD-RS-5, Vanderbilt, or Conners at baseline and after every dose change rather than by impression alone.
• Routine ECG and laboratory monitoring are not required; obtain ECG or cardiology input only when history, exam, or symptoms suggest cardiac disease.
• Reassess diversion risk, early refill requests, and lost prescriptions at every visit and check the state prescription drug monitoring program.

Interactions

• Contraindicated within 14 days of an MAOI including phenelzine, tranylcypromine, selegiline, and linezolid because of hypertensive crisis risk.
• CYP-mediated interactions are minimal, but methylphenidate can inhibit clearance of warfarin, phenytoin, and tricyclic antidepressants, raising levels.
• Additive sympathomimetic effects with decongestants, other stimulants, and SNRIs raise blood pressure and heart rate; monitor vitals when combined.
• Halogenated anesthetics can trigger abrupt blood pressure and heart rate rises, so hold the stimulant on the morning of elective surgery.
• Gastric alkalinizers speed release of some ER capsules while acidifying agents slow absorption; the effect is smaller than it is with amphetamines.

Special populations

• Pregnancy: no clear teratogenic signal, though registry data suggest a small absolute rise in cardiac malformations; continue only if benefit outweighs risk.
• Lactation: transferred in small amounts with relative infant dose under 1 percent, so it is generally considered compatible with breastfeeding.
• Pediatric: labeled from age 6 years; preschool use is off-label and behavioral parent training should be tried first per AAP guidance.
• Geriatric: start at the low end and watch blood pressure, arrhythmia, anorexia, and delirium; evidence for apathy in dementia remains limited.
• No dose change is required in renal or hepatic impairment because clearance depends on plasma and tissue carboxylesterase rather than liver or kidney.

Clinical pearls

• Duration of action, not half-life, drives product choice; match the delivery system to the patient's day.
• Failing methylphenidate does not predict failing amphetamine; roughly 40 percent respond to the other class.
• Manage appetite loss by feeding around the dose rather than by lowering an otherwise effective dose.